Published · Aurelis Peptides
Ipamorelin and sermorelin are separate peptides associated with growth-hormone release. Ipamorelin is a five-amino-acid peptide. Sermorelin is the 29-amino-acid, amide-ended fragment of growth-hormone-releasing hormone, or GHRH. Their names identify different molecular structures, even when they appear in the same research category. Ipamorelin discovery paper · NLM Sermorelin identity record.
There is also a catalogue distinction. Aurelis lists Sermorelin 10 mg as its own entry. Ipamorelin appears in the Ipamorelin + CJC (no DAC) blend, with the complete specification on request.
Ipamorelin vs sermorelin at a glance
| Compare | Ipamorelin | Sermorelin |
|---|---|---|
| Peptide identity | Synthetic pentapeptide: five amino acids | GHRH(1–29)-amide fragment |
| Research distinction | GHRP-like receptor activity in the original pharmacology study | GHRH fragment associated with the releasing-hormone pathway |
| Current listed presentation | Part of Ipamorelin + CJC (no DAC) | Standalone Sermorelin entry |
| Listed content | Complete blend specification on request | 10 mg per unit |
| Keep visible in an enquiry | Both component names and no DAC designation | Sermorelin name and selected listed content |
What did the ipamorelin study examine?
Raun and colleagues introduced ipamorelin in 1998. They examined growth-hormone release in primary rat pituitary cells, rats and swine. A secretagogue is a substance that stimulates secretion; here, the measured secretion was growth hormone.
The researchers used receptor-blocking compounds to help identify the pathway involved. Their results placed ipamorelin's activity with a GHRP-like receptor rather than the GHRH receptor pathway. They also compared hormone-release selectivity in the animal experiments. Read Raun et al., 1998.
Those observations explain the original research classification. They do not provide a direct ipamorelin-versus-sermorelin treatment comparison or test the Aurelis combined presentation.
Where does sermorelin fit?
GHRH means growth-hormone-releasing hormone. Sermorelin's GHRH(1–29)-amide name specifies a particular fragment of that hormone. The National Library of Medicine records that identity and related names, including GRF(1–29)NH2. See the identity record.
Research on the human GHRH receptor helps explain the releasing-hormone pathway. Gaylinn and colleagues expressed the receptor in cultured cells and measured GHRH binding and an internal cell signal called cyclic AMP. Read the 1993 receptor study.
A separate 1984 study compared three GHRH peptide lengths, including the 1–29 fragment, in five healthy volunteers. It measured growth-hormone levels in blood. The selected studies concern receptor signalling and hormone response; they do not establish a ranking of weight loss, muscle gain or recovery. Read Losa et al., 1984.
Why the blend name changes the comparison
An enquiry for Ipamorelin alone and one for Ipamorelin + CJC (no DAC) describe different material requests. The latter includes a second named component. Aurelis has no current standalone Ipamorelin catalogue entry.
The existing blend source does not settle the CJC component amount, combined total or ratio. Keep those fields open until a complete formulation is supplied. Do not turn the abbreviated blend name into a confirmed equal-parts mixture. The CJC DAC vs no DAC guide handles the naming distinction in more detail.
What does Sermorelin 10 mg describe?
The 10 mg listing describes content per unit. It does not specify a liquid concentration, a delivered amount or how the material should be used. It also cannot be compared numerically with an unresolved blend total. Our content and concentration guide explains the unit distinction.
For other comparisons, use the Tesamorelin vs Sermorelin guide. That page asks a different question about two GHRH-related names; it should not be substituted for the Ipamorelin comparison here.
Prepare a precise product enquiry
Both vials and pen-style kits remain format enquiries. Request the offered presentation for the exact entry, including its contents and unit count. Packaging appearance does not establish a compound's identity or complete a blend specification.
Include the full product name, requested quantity and destination in Australia, Canada or the USA. Ask the team to confirm current local availability and provide matching product and batch documentation. Send a focused enquiry or email sales@aurelispeptides.com.
Research and identity sources
- Raun et al., European Journal of Endocrinology, 1998 — ipamorelin identity, pharmacology and selected experimental models.
- National Library of Medicine, MeSH: Sermorelin — GHRH(1–29)-amide identity and related terms.
- Gaylinn et al., Molecular Endocrinology, 1993 — human GHRH receptor binding and signalling in cultured cells.
- Losa et al., Klinische Wochenschrift, 1984 — three GHRH fragment lengths and blood hormone measurements.